Back to search results

The CONQUER Trial: Quitting Vaping with VapeAway

This study, called the CONQUER Trial, is testing a new program called VapeAway to help adults quit using nicotine e-cigarettes (vaping). The VapeAway system uses special filters to gradually reduce nicotine, a "Fix Bar" for behavioral support, and a digital support system. We are looking for about 70 adults, aged 21 and older, who vape daily or almost daily and are motivated to quit. The main goal is to see how many people can successfully stop vaping within 90 days. We will also check your saliva for cotinine, a marker of nicotine use, to confirm eligibility.

Study design
This is a single-arm, open-label study, meaning all 70 participants will receive the VapeAway intervention. It is a Phase II trial.
What's involved
You would use the VapeAway system for about 42 days, and the total study duration for you would be around 90 days.
Compensation
Not stated in the trial record.
Follow-up
The main goal is measured up to 90 days after starting the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07322432

The CONQUER Trial - Cessation Of Nicotine, QUitting With E-cigarette Reduction

Recruiting
PHASE2Ages 21+Interventional
VapeAway
~70 participants
Updated 2026-01-07 on ClinicalTrials.gov
What's tested:VapeAway filter system

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Vaping Cessation
Measured over up to 90 days

Conditions

Addiction Nicotine

Explore related trials

Nicotine DependenceVaping Addiction

Where it's being run

1 sites across 1 states
New York1

Study leadership

  • Mendel Goldfinger, MD · PRINCIPAL_INVESTIGATOR · VapeAway

Who to contact

Sarah Clinical Trial Manager, PhD
[email protected]
2017548404
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age: Adults aged 21 years and older
Current Vaping Behavior: Daily or near-daily use (≥5 days/week or at least 20 days per month) of nicotine-containing e-cigarettes for at least the past 3 months.
Motivation and desire to quit as determined by all of the following three assessment tools:
Score of 4 or 5 on all 5-point Likert-type scale questions (see appendix)
Score of 6 or 7 on Motivation To Stop Scale (MTSS) (see appendix)
Participants must be classified in the Preparation stage of the Transtheoretical Model of behavior change (see appendix)
Saliva Cotinine level ≥ 10 ng/ml
Penn State Electronic Cigarette Dependence Index (PSECDI) of at least 4 and above
Willingness to participate in the study and all study requirements
Willingness to not use any other nicotine-containing products for the duration of the study
Ability to attend visits and provide informed consent

Exclusion

Mental Health Concerns with a score above the following thresholds:
PHQ-2 score ≥ 2 (see appendix)
GAD-2 score ≥ 2 (see appendix)
Use of Other Tobacco or Nicotine Products:
Use of any nicotine products except for vaping, including combustible tobacco (e.g., cigarettes) or other non-e-cigarette nicotine delivery systems within the past 30-days
Current Substance or alcohol Use Disorder:
Self-reported or medically diagnosed substance use disorder (excluding nicotine), unless in sustained remission (\>12 months).
Illicit drug use in the past 60 days
Screening positive for alcohol use disorder in past year
Medical Contraindications:
Any serious medical condition or medication that would contraindicate participation in a behavioral cessation trial (to be defined and assessed by study physician or PI).
Pregnant or breastfeeding
Symptomatic cardiovascular disease
Participation in another smoking/vaping cessation trial

What this trial measures

  • Vaping Cessationup to 90 days

    To determine the prevalence of vaping abstinence (quit rates) with the VapeAway system at 30 days after completion of the program (intervention period) verified by self-reporting and biochemical testing